While Teva- Pharmaceutical Industries Ltd. ADR has underperformed by -1.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TEVA rose by 76.68%, with highs and lows ranging from $19.31 to $9.35, whereas the simple moving average jumped by 5.78% in the last 200 days.
On July 10, 2024, Argus Upgraded Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) to Buy. A report published by JP Morgan on March 08, 2024, Upgraded its rating to ‘Neutral’ for TEVA. Piper Sandler also Upgraded TEVA shares as ‘Overweight’, setting a target price of $19 on the company’s shares in a report dated February 12, 2024. Jefferies January 23, 2024d the rating to Buy on January 23, 2024, and set its price target from $10 to $14. Piper Sandler January 03, 2024d its ‘Underweight’ rating to ‘Neutral’ for TEVA, as published in its report on January 03, 2024. HSBC Securities’s report from December 18, 2023 suggests a price prediction of $13 for TEVA shares, giving the stock a ‘Buy’ rating. UBS also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Further, the quarter-over-quarter increase in sales is 13.40%, showing a positive trend in the upcoming months.
One of the most important indicators of Teva- Pharmaceutical Industries Ltd. ADR’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -14.76% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.61, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and TEVA is recording 6.82M average volume. On a monthly basis, the volatility of the stock is set at 2.70%, whereas on a weekly basis, it is put at 3.62%, with a loss of -1.03% over the past seven days. Furthermore, long-term investors anticipate a median target price of $23.00, showing growth from the present price of $17.35, which can serve as yet another indication of whether TEVA is worth investing in or should be passed over.
How Do You Analyze Teva- Pharmaceutical Industries Ltd. ADR Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.01%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 56.89% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TEVA shares are owned by institutional investors to the tune of 56.89% at present.
